News | September 12, 2012

New source of nuclear imaging tracers will offer alternative source for radiopharmaceuticals

September 12, 2012  – Positron Corp. announced that Jubilant DraxImage Inc., a Jubilant Life Sciences company, and Positron, have executed a Letter of Intent pertaining to:

  • Positron's supply of Active Pharmaceutical Ingredient (API) grade strontium (Sr)-82 for the JDI Sr-82/rubidium (Rb)-82 generator;
  • JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users (upon FDA clearance); and
  • Positron's lifecycle management for expired JDI Sr-82/Rb-82 generators.

 

The strategic alliance between JDI and Positron will facilitate the stabilization, security and growth of the industry by increasing the supply of radioisotopes and radiopharmaceuticals. The parties expect that it will also provide considerable benefits to both parties: Positron secures a generator supply for future sales of cardiac positron emission tomography (PET) scanners and a customer for Sr-82; JDI secures a reliable supply of Sr-82, a vendor for expired generators management and a strategic partner with a growing customer base of cardiac PET scanners installed and serviced.

Martyn Coombs, president of JDI, stated, "Through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), Positron positioned itself as the only private entity in the United States with the practical experience of servicing the Sr-82/Rb-82 generator lifecycle. Their ability to provide a more stable and secure supply of API Sr-82 and management of expired Sr-82/Rb-82 generators fits well with JDI's pre-launch strategy."

Patrick Rooney, chief executive officer of Positron, stated, "JDI has developed a robust Sr-82/Rb-82 generator and elution system. As the Sr-82/Rb-82 generator on the market has enjoyed tremendous growth and the merits of the technology have been validated many times over, we strongly believe that the arrival of an alternative, upon the U.S. Food and Drug Administration (FDA) clearance of JDI's generator, will be welcomed by the cardiac PET community."

JDI and Positron expect to complete a Definitive Agreement within three months.

For more information: www.draximage.com and www.positron.com


Related Content

Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
News | PET-CT

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
arrow
News | PET-CT

September 7, 2023 — The groundbreaking AURA 10 specimen imager by Belgian MedTech pioneer XEOS has been cleared by the ...

Time September 07, 2023
arrow
Feature | PET Imaging

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
arrow
News | Radiopharmaceuticals and Tracers

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 31, 2023
arrow
News | Radiopharmaceuticals and Tracers

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

Time August 29, 2023
arrow
Subscribe Now